Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus TRIACIN C.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus TRIACIN C.
CORTENEMA vs TRIACIN-C
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
TRIACIN-C is a combination of triamcinolone (a corticosteroid) and nystatin (an antifungal). Triamcinolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Nystatin binds to ergosterol in fungal cell membranes, causing pore formation and cell death.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
5 mg orally twice daily, taken with meals to enhance absorption.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life: 7–9 hours. In patients with severe hepatic impairment (Child-Pugh C), half-life may extend to 15 hours; dosing adjustment recommended.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal: ~60% as unchanged drug; hepatic metabolism accounts for ~25% (primarily via CYP3A4), with biliary excretion of metabolites (~15%); fecal elimination <5%.
Category C
Category C
Corticosteroid
Corticosteroid